All News


All series


All All News

The Food and Drug Administration (FDA) granted a priority review to a biologics license application (BLA) for an immunotherapy agent – cemiplimab – to be used to treat metastatic cutaneous squamous cell carcinoma (a type of skin cancer; CSCC) or patients with locally advanced CSCC who are not eligible for surgery.

When I contemplate this latest benchmark in my life, my 15th year surviving stage 3b breast cancer, I confess there are times when I feel like it was just yesterday the Trickster Coyote – the Native American mythical creature of evil and bad omen – blindsided me, bent on taking me down in the one sacred place I felt I could take refuge from the world: my home.

The Food and Drug Administration (FDA) granted a priority review to a supplemental biologics license application (sBLA) for frontline Keytruda (pembrolizumab) for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC), according to Merck (MSD), the manufacturer of the PD-1 inhibitor.

This month at CURE, we’re kicking off a social media campaign that gives you the chance to show off your accomplishments, big and small, while inspiring others like you to do the same: Show the world what you #CanDoWithCancer.

For those of us living with (and taking care of) people living with brain tumors, cancers and other diseases that become chronic, life's challenges begin to shift, as do our outlooks. It is important for us to be able to love our bodies, our disabilities, and for the world to make space for all sorts of bodies to exist.

Compare it to needing chemo for cancer or a cast for a broken arm. You wouldn't say no to either of those, but why are people hesitant to try care for mental health?